Millennium Predictive's Outcome
Executive Summary
Millennium Pharmaceuticals' new collaboration with Roche Diagnostics to develop prognostic and therapeutic information products in rheumatoid arthritis is notable as being only the second molecular diagnostics discovery deal involving the delivery of targets to a large diagnostics company (the first being Millennium's Becton Dickinson deal in cancer). But the news behind the scenes is that Millennium has also quietly re-integrated two of the three programs in its Predictive Medicine subsidiary, setting the stage for the roll-out of a major, web-based personalized medical information play, most likely by year-end.You may also be interested in...
Big Diagnostics Companies See the Genomics Light
Until now, large diagnostics companies have been slow to get involved in the industry's biggest paradigm shift in a decade: the move to molecular markers that will help make diagnostics part of the treatment process. At this year's AACC, the small companies leading the way in this field were beginning to make their presence felt. And the big companies, J&J, Roche, Abbott, Beckman, were starting to talk about their own programs in the field. But they're moving slowly in a fast-moving field, and thus are vulnerable to new competitors.
Viatris Will Tread A Different Path
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
EU Single Patent System On Course For 2020
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports